Corvus Pharmaceuticals Inc. (CRVS)’s Financial Results Comparing With XBiotech Inc. (NASDAQ:XBIT)

We will be contrasting the differences between Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) and XBiotech Inc. (NASDAQ:XBIT) as far as institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corvus Pharmaceuticals Inc. N/A 0.00 44.28M -1.75 0.00
XBiotech Inc. N/A 0.00 22.93M -0.64 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 shows Corvus Pharmaceuticals Inc. and XBiotech Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Corvus Pharmaceuticals Inc. 0.00% -38.7% -35.7%
XBiotech Inc. 0.00% -51.9% -48.9%


The Current Ratio of Corvus Pharmaceuticals Inc. is 12.4 while its Quick Ratio stands at 12.4. The Current Ratio of rival XBiotech Inc. is 4.6 and its Quick Ratio is has 4.6. Corvus Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than XBiotech Inc.

Institutional & Insider Ownership

The shares of both Corvus Pharmaceuticals Inc. and XBiotech Inc. are owned by institutional investors at 86% and 13.5% respectively. Corvus Pharmaceuticals Inc.’s share owned by insiders are 0.9%. Comparatively, 37.8% are XBiotech Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Corvus Pharmaceuticals Inc. 9.63% 14.43% 3.98% -43.87% -54.83% 20.98%
XBiotech Inc. -1.05% 4.56% 14.22% 144.16% 114.12% 85.04%

For the past year Corvus Pharmaceuticals Inc. has weaker performance than XBiotech Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.